1. Home
  2. LPTX vs CARM Comparison

LPTX vs CARM Comparison

Compare LPTX & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • CARM
  • Stock Information
  • Founded
  • LPTX 2011
  • CARM 2016
  • Country
  • LPTX United States
  • CARM United States
  • Employees
  • LPTX N/A
  • CARM N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • CARM Biotechnology: Pharmaceutical Preparations
  • Sector
  • LPTX Health Care
  • CARM Health Care
  • Exchange
  • LPTX Nasdaq
  • CARM Nasdaq
  • Market Cap
  • LPTX 11.1M
  • CARM 12.2M
  • IPO Year
  • LPTX N/A
  • CARM N/A
  • Fundamental
  • Price
  • LPTX $0.31
  • CARM $0.32
  • Analyst Decision
  • LPTX Hold
  • CARM Hold
  • Analyst Count
  • LPTX 1
  • CARM 5
  • Target Price
  • LPTX N/A
  • CARM $0.90
  • AVG Volume (30 Days)
  • LPTX 710.1K
  • CARM 25.7M
  • Earning Date
  • LPTX 11-12-2025
  • CARM 11-06-2025
  • Dividend Yield
  • LPTX N/A
  • CARM N/A
  • EPS Growth
  • LPTX N/A
  • CARM N/A
  • EPS
  • LPTX N/A
  • CARM N/A
  • Revenue
  • LPTX N/A
  • CARM $10,767,000.00
  • Revenue This Year
  • LPTX N/A
  • CARM N/A
  • Revenue Next Year
  • LPTX N/A
  • CARM N/A
  • P/E Ratio
  • LPTX N/A
  • CARM N/A
  • Revenue Growth
  • LPTX N/A
  • CARM N/A
  • 52 Week Low
  • LPTX $0.22
  • CARM $0.14
  • 52 Week High
  • LPTX $4.79
  • CARM $1.27
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 53.90
  • CARM 49.31
  • Support Level
  • LPTX $0.28
  • CARM $0.31
  • Resistance Level
  • LPTX $0.32
  • CARM $0.39
  • Average True Range (ATR)
  • LPTX 0.02
  • CARM 0.06
  • MACD
  • LPTX 0.00
  • CARM -0.00
  • Stochastic Oscillator
  • LPTX 73.33
  • CARM 33.45

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

About CARM Carisma Therapeutics Inc.

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Share on Social Networks: